BACKGROUND AND AIMS The aim was to derive health state utility scores in ulcerative colitis (UC) by establishing the relationship between the physician-rated ulcerative colitis disease activity index (UCDAI) and a patient reported EQ-5D by statistically mapping the two instruments. METHODS In a randomised controlled trial comparing oral plus enema mesalazine treatment with oral mesalazine tre...

Abstract Background Ulcerative colitis (UC) incidence has bimodal age distribution with a peak in the second to fourth decade and smaller sixth eighth decade. We assessed difference rates of clinical endoscopic response remission adult (≤60 years age) elderly (>60 mild-to-moderate (Mayo Clinic Score ≥5) UC patients treated mesalazine. Methods performed post-hoc analysis data from phase 3...

BACKGROUND Patients with refractory-ulcerative colitis (UC) require therapy escalation. Sulfasalazine (SASP) could deliver a high concentration of 5-aminosalicylic acid to the colon. The usefulness of SASP for refractory-UC patients, however, is unclear. AIM The aim was to evaluate the usefulness of SASP for refractory-UC patients. METHOD We retrospectively analysed 36 (11.4%) of 316 patien...

Abstract Background Background: It has been postulated that early treatment of inflammatory bowel disease (IBD) is associated with a better long-term response. In Catalonia, the detection program for colorectal cancer (EDPCRC) active since 2010, and was extended to entire Catalan territory in 2015. The aim this study describe natural history IBD asymptomatic diagnosed through EDPCRC Catalonia. ...

We describe an axonal motor polyneuropathy in a patient with ulcerative colitis. Symptoms of neuropathy occurred during active colitis. Electrophysiological study showed motor axonal degeneration. After treatment with steroid added to mesalazine, the patient had a gastrointestinal recovery and neurological symptoms were improved. Axonal motor polyneuropathy is an unusual extraintestinal manifes...

5-Aminosalicylic acid (5-ASA) compounds occasionally exacerbate diarrhoea in patients with inflammatory bowel disease. This is thought to be due to a secretory mechanism in most cases. A patient with presumed intolerance to sulphasalazine and 5-ASA preparations who developed endoscopic and histological evidence of disease relapse after a rectal challenge with mesalazine is reported.

BACKGROUND Previous studies reported that nephrotic syndrome is associated with ulcerative colitis (UC) patients treated with mesalazine. Dysplasia associated with UC often develops into colorectal carcinoma. CASE PRESENTATION A 17-year-old man was referred to our hospital, complaining of diarrhea and bloody stool. Total colonoscopy (TC) was performed and total-type UC was diagnosed. After tr...